Ro 3306

Bezeichnung:Ro 3306

CAS-Nr872573-93-8

Englisch Name:Ro 3306

CBNumberCB92535693

SummenformelC18H13N3OS2

Molgewicht351.45

MOL-Datei872573-93-8.mol

Ro 3306 physikalisch-chemischer Eigenschaften

Siedepunkt	569.1±60.0 °C(Predicted)
Dichte	1.41
storage temp.	2-8°C
Löslichkeit	DMSO: soluble5mg/mL, clear
pka	3.99±0.10(Predicted)
Aggregatzustand	powder
Farbe	white to light brown
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Sicherheit

WGK Germany

Ro 3306 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
RO-3306 (872573-93-8) is a selective inhibitor of CDK1 (IC50?= 35 nM versus CDK2 IC50?= 340nM).1,2?It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4?It has also been demonstrated to overcome apoptotic resistance in BRAFV600E?human colorectal cancer cells.5
Verwenden
RO-3306 is an ATP-competitive and selective CDK1 inhibitor used against a diverse panel of human kinases. Used in the treatment of malignant tumors in conjunction with PARP inhibitors.
Verwenden
RO-3306 has been used:
- To study the significance of CA4-mediated cytotoxicity in mitotic arrest
- In cell cycle synchronization to conduct a study on proteomics
- As a CDK1 inhibitor, to prevent early mitotic entry
Biochem/physiol Actions
RO-3306 is a selective ATP-competitive inhibitor of CDK1. It inhibites CDK1 cyclin B1 activity with Ki of 35 nM, nearly 10-fold selectivity relative to CDK2/cyclin E and over 50-fold relative to CDK4/cyclin D. RO-3306 has been used to cause cell cycle arrest at the G2/M boundary.
Lager
Store at +4°C
Einzelnachweise
1) Vassilev?et al.?(2006),?Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1; Proc. Nat. Acad. Sci. USA?103?10660 2) Krasinska?et al.?(2008),?Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle; Cell Cycle?7?1702 3) Pierce?et al.?(2013),?Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines; Cancer Biol. Ther.?14?537 4) Xia?et al.?(2014),?The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition;?Int. J. Oncol.?44?735 5) Zhang?et al.?(2018),?Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer; Mol. Cancer Res.?16?378

Ro 3306 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

872573-93-8, Ro 3306 Verwandte Suche:

Send Inquriy